创仿并重，齐鲁制药彰显民族药企科技创新硬实力

Core Insights - The Chinese pharmaceutical industry is currently the second largest in the world, having significantly improved its competitiveness over the past decade, transitioning from "catching up" to "keeping pace" and even "leading" in certain areas [1] - Qilu Pharmaceutical, as a representative of national pharmaceutical companies, is committed to high-quality development and has made substantial contributions to the industry [1] Group 1: National Drug Procurement Participation - By November 2025, Qilu Pharmaceutical has 109 products that have been awarded bids or renewed, with 30 of these drugs also being exported to 33 countries and regions, benefiting both domestic and global patients [2] - The drug Medaxin, included in the national drug procurement list, has successfully replaced original research drugs, demonstrating excellent performance in real-world studies, with data from nearly 360,000 patients confirming its efficacy and safety [2] - Medaxin has benefited over 100 million cardiovascular disease patients in China, significantly reducing their economic burden of medication and exemplifying the active participation of national pharmaceutical companies in drug procurement [2] Group 2: Global Reach and Quality Assurance - Qilu Pharmaceutical's products benefit approximately 1.5 billion people globally each year, adhering to the principle of "global uniformity and shared production lines," ensuring high standards for both domestic and international markets [3] - Since 2013, Qilu Pharmaceutical has implemented a "dual reporting" system for drug approvals, submitting the same products for registration with both the Chinese National Medical Products Administration and international regulatory bodies [3] - The company has established multiple collaborations with international organizations, including the United Nations Development Programme, to enhance global public health accessibility and has expanded its market presence in emerging regions such as the Middle East, North Africa, Central Asia, Southeast Asia, and Latin America [3]